Answers are grounded in this paper and cite their sources.
Introduction/Background Vulvar cancers(VC) are uncommon and affect predominantly elderly women. Incidence is increasing over the last decades, especially in women <60 years. High recurrence and morbimortality rates are described. The most well-known risks factors of recurrence are: lymph node involvement(N+), tumour size and presence of vulvar intraepithelial neoplasia(VIN). Study objectives - Main objective: to describe recurrence rate(RR) of VC in our centre. - Secondary objectives: to know the five years overall survival(OS), disease specific survival(DSS), Event-free survival(EFS) of VC-patients treated in our centre. To compare OS, DSS, EFS and RR when N+ and in cases with margins of resection are affected by VIN. Methodology Unicentric retrospective observational study Patients treated for VC with a curative intention under follow-up in our centre between 2005 and 2020. Statistical analysis performed with SPSS(v28). Excluding criteria: non-squamous cell carcinoma, loss of follow-up, debulking or palliative surgeries. Results 46 patients were included. The mean age was 73 years(33–91). 17 patients presented a recurrence(RR 37%). Five-year OS and DSS were 30% and 50% respectively. 80% of patients treated on 2020 were free of disease. Patients with N+ presented a higher RR (X² p<0.05). OS(long rank p=0,088), DSS(long rank p<0.05) and EFS(long rank p<0.05) were poorer in patients with N+. Patients with VIN on margins presented poorest results buy they did not have achieved statistical signification(RR, OS, DSS, EFS p>0.05). Conclusion Our study population had a RR similar to literature data. However we detected a poorer OS and DSS than literature data. These might be explained by an elderly study population with high comorbidities. Patients with N+ had worse results with higher RR both local or on inguinal nodes. Patients with VIN affecting margins presented higher RR but without statistical significance, perhaps due to a small sample, which might be the main limitation of our study. Disclosures No.
No takes yet. Share an insight, caveat, or question.
Doradop et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: